Taxus Cardium Pharmaceuticals Stock Current Valuation
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
Valuation analysis of Taxus Cardium Pharma helps investors to measure Taxus Cardium's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Taxus Cardium's price fluctuation is very steady at this time. Calculation of the real value of Taxus Cardium Pharma is based on 3 months time horizon. Increasing Taxus Cardium's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Taxus pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Taxus Cardium Pharmaceuticals. Since Taxus Cardium is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Taxus Pink Sheet. However, Taxus Cardium's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.5E-5 | Hype 1.0E-4 |
The intrinsic value of Taxus Cardium's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Taxus Cardium's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Taxus Cardium Pharmaceuticals helps investors to forecast how Taxus pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Taxus Cardium more accurately as focusing exclusively on Taxus Cardium's fundamentals will not take into account other important factors: Taxus Cardium Pharmaceuticals Company Current Valuation Analysis
Taxus Cardium's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Taxus Cardium Current Valuation | 881.11 K |
Most of Taxus Cardium's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taxus Cardium Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Taxus Cardium Pharmaceuticals has a Current Valuation of 881.11 K. This is 99.99% lower than that of the Biotechnology sector and 99.98% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Taxus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taxus Cardium's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Taxus Cardium could also be used in its relative valuation, which is a method of valuing Taxus Cardium by comparing valuation metrics of similar companies.Taxus Cardium is currently under evaluation in current valuation category among its peers.
Taxus Fundamentals
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Number Of Shares Shorted | 150.25 K | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Net Income | (517.9 K) | |||
| Cash And Equivalents | 386.03 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.26 M | |||
| Debt To Equity | (1.01) % | |||
| Current Ratio | 0.08 X | |||
| Book Value Per Share | (0.1) X | |||
| Cash Flow From Operations | (1.13 M) | |||
| Short Ratio | 1.03 X | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 2.0 | |||
| Beta | -48.52 | |||
| Market Capitalization | 64 | |||
| Total Asset | 566.98 K | |||
| Retained Earnings | (114.05 M) | |||
| Working Capital | (3.8 M) | |||
| Current Asset | 30.78 K | |||
| Current Liabilities | 3.83 M | |||
| Net Asset | 566.98 K |
About Taxus Cardium Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taxus Cardium Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taxus Cardium using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taxus Cardium Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |